Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | MAOB | P27338 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 5/20 | 0.44 |
| ▸ | MMP2 | P08253 | 5/20 | 0.44 |
| ▸ | MMP9 | P14780 | 5/20 | 0.44 |
| ▸ | CBS | P35520 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4277198 | 1.00 | MAPT (0.49) | MAPTNPC1MAOBRAB9AMEN1 | |
| SCHEMBL4280130 | 0.89 | MAPT (0.51) | MAPTNPC1MAOBRAB9AMEN1 | |
| SCHEMBL4280129 | 0.89 | MAPT (0.51) | MAPTNPC1MAOBRAB9AMEN1 | |
| SCHEMBL13879593 | 0.89 | LTB4R (0.49) | MAPTNPC1MAOBRAB9AMEN1 | |
| SCHEMBL4281398 | 0.85 | MAPT (0.45) | MAPTNPC1MAOBRAB9AMEN1 | |
| SCHEMBL4281400 | 0.85 | MAPT (0.45) | MAPTNPC1MAOBRAB9AMEN1 | |
| SCHEMBL27751383 | 0.83 | LTB4R (0.42) | MAPTNPC1MAOBRAB9AMEN1 | |
| SCHEMBL8058649 | 0.81 | MAPT (0.62) | MAPTNPC1MAOBRAB9AMEN1 | |
| SCHEMBL8058647 | 0.81 | MAPT (0.62) | MAPTNPC1MAOBRAB9AMEN1 | |
| SCHEMBL8059583 | 0.79 | MAPT (0.74) | MAPTNPC1MAOBRAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| EP-1943228-A2 | INHIBITORS OF VIRAL REPLICATION | Intermune, Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007047146-A2 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, RTF2 | MAPT 4203/4885NPC1 680/4885MAOB 2266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.